Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.63 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236970 | 0.82 | KDM4E (0.69) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL2888000 | 0.82 | KDM4E (0.69) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL29855719 | 0.82 | MAPT (0.69) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL5263677 | 0.82 | MAPT (0.69) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL1655185 | 0.82 | PRKD1 (0.84) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL6350624 | 0.82 | KDM4E (0.69) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL6241086 | 0.82 | KDM4E (1.00) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL11271957 | 0.79 | KDM4E (0.66) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL797563 | 0.79 | KDM4E (1.00) | KDM4EMAPTALDH1A1LMNAHPGD | |
| SCHEMBL34463671 | 0.78 | KDM4E (1.00) | KDM4EMAPTALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | KDM4E 1947/4885MAPT 1892/4885ALDH1A1 4386/4885 |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | KDM4E 2254/4885MAPT 2076/4885ALDH1A1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.